Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
McKesson
Chinese Patent Office
Cantor Fitzgerald
UBS
Merck
AstraZeneca
Argus Health
Medtronic

Generated: July 19, 2018

DrugPatentWatch Database Preview

Taro Pharm Inds Ltd Company Profile

« Back to Dashboard

What is the competitive landscape for TARO PHARM INDS LTD, and what generic alternatives to TARO PHARM INDS LTD drugs are available?

TARO PHARM INDS LTD has nineteen approved drugs.

There are two US patents protecting TARO PHARM INDS LTD drugs.

There are ten patent family members on TARO PHARM INDS LTD drugs in seven countries and nine supplementary protection certificates in four countries.

Summary for Taro Pharm Inds Ltd
International Patents:10
US Patents:2
Tradenames:11
Ingredients:9
NDAs:19

Drugs and US Patents for Taro Pharm Inds Ltd

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Taro Pharm Inds Ltd HYDROCORTISONE AND ACETIC ACID acetic acid, glacial; hydrocortisone SOLUTION/DROPS;OTIC 088759-001 Mar 4, 1985 AT RX No No ➤ Sign Up ➤ Sign Up
Taro Pharm Inds Ltd ACETAMINOPHEN acetaminophen SUPPOSITORY;RECTAL 018337-003 Sep 12, 1983 OTC Yes No ➤ Sign Up ➤ Sign Up
Taro Pharm Inds Ltd TOPICORT desoximetasone GEL;TOPICAL 074904-001 Jul 14, 1998 AB RX No Yes ➤ Sign Up ➤ Sign Up
Taro Pharm Inds Ltd TOPICORT desoximetasone CREAM;TOPICAL 073210-001 Nov 30, 1990 AB RX No Yes ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TARO PHARM INDS LTD drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Topical Spray 0.25% ➤ Subscribe 2013-12-18
➤ Subscribe Topical Lotion 0.5% ➤ Subscribe 2011-03-16

Non-Orange Book US Patents for Taro Pharm Inds Ltd

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,039,657 Process for preparing malathion for pharmaceutical use ➤ Sign Up
8,957,238 Process for preparing malathion for pharmaceutical use ➤ Sign Up
8,536,155 Process for preparing malathion for pharmaceutical use ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Taro Pharm Inds Ltd Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00085 Netherlands ➤ Sign Up PRODUCT NAME: LEVOCETIRIZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER LEVOCETIRINE DIHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 26770 20011009; FIRST REGISTRATION: DE 49903.00.00 AND 49904.00.00 20010103
01C/013 Belgium ➤ Sign Up PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
C/GB08/005 United Kingdom ➤ Sign Up SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
C/GB11/054 United Kingdom ➤ Sign Up PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Baxter
Express Scripts
Harvard Business School
Accenture
Dow
Teva
Chinese Patent Office
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.